EDWARDS LIFESCIENCES CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - CHF | -.--% |
|
-.--% | -.--% |
| 06-20 | Edwards Lifesciences Insider Sold Shares Worth $492,258, According to a Recent SEC Filing | MT |
| 06-17 | Edwards Lifesciences Corporation Announces Executive Changes | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The opinion of analysts covering the stock has improved over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 34.65 and 29.48 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -.--% | 54.88B | - | ||
| +5.16% | 212B | B | ||
| +9.62% | 188B | B- | ||
| +31.18% | 157B | B- | ||
| +33.37% | 114B | A- | ||
| +3.46% | 64.01B | A- | ||
| +1.51% | 48.83B | B+ | ||
| -4.27% | 39.3B | A | ||
| +0.88% | 35.97B | - | ||
| +8.44% | 27B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EW Stock
- 0REN Stock
- Ratings Edwards Lifesciences Corporation
